ES2227671T3 - Uso de una texafirina en la preparacion de un medicamento para usar con un agente quimioterapeutico en la quimiosensibilizacion del cancer. - Google Patents

Uso de una texafirina en la preparacion de un medicamento para usar con un agente quimioterapeutico en la quimiosensibilizacion del cancer.

Info

Publication number
ES2227671T3
ES2227671T3 ES97903873T ES97903873T ES2227671T3 ES 2227671 T3 ES2227671 T3 ES 2227671T3 ES 97903873 T ES97903873 T ES 97903873T ES 97903873 T ES97903873 T ES 97903873T ES 2227671 T3 ES2227671 T3 ES 2227671T3
Authority
ES
Spain
Prior art keywords
texaphyrin
iii
use according
metal cation
chemotherapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97903873T
Other languages
English (en)
Spanish (es)
Inventor
Richard A. Miller
Stuart W. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacyclics LLC
Original Assignee
Pharmacyclics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics LLC filed Critical Pharmacyclics LLC
Application granted granted Critical
Publication of ES2227671T3 publication Critical patent/ES2227671T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES97903873T 1996-01-25 1997-01-23 Uso de una texafirina en la preparacion de un medicamento para usar con un agente quimioterapeutico en la quimiosensibilizacion del cancer. Expired - Lifetime ES2227671T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/591,318 US5776925A (en) 1996-01-25 1996-01-25 Methods for cancer chemosensitization
US591318 1996-01-25

Publications (1)

Publication Number Publication Date
ES2227671T3 true ES2227671T3 (es) 2005-04-01

Family

ID=24366012

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97903873T Expired - Lifetime ES2227671T3 (es) 1996-01-25 1997-01-23 Uso de una texafirina en la preparacion de un medicamento para usar con un agente quimioterapeutico en la quimiosensibilizacion del cancer.

Country Status (13)

Country Link
US (1) US5776925A (cg-RX-API-DMAC7.html)
EP (1) EP0912196B9 (cg-RX-API-DMAC7.html)
JP (1) JP2000503989A (cg-RX-API-DMAC7.html)
KR (1) KR19990082024A (cg-RX-API-DMAC7.html)
CN (1) CN1093766C (cg-RX-API-DMAC7.html)
AT (1) ATE277637T1 (cg-RX-API-DMAC7.html)
AU (1) AU715025B2 (cg-RX-API-DMAC7.html)
DE (1) DE69730961T2 (cg-RX-API-DMAC7.html)
ES (1) ES2227671T3 (cg-RX-API-DMAC7.html)
IL (1) IL125459A0 (cg-RX-API-DMAC7.html)
NO (1) NO983429L (cg-RX-API-DMAC7.html)
NZ (1) NZ331513A (cg-RX-API-DMAC7.html)
WO (1) WO1997026915A1 (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US6482436B1 (en) 1993-01-29 2002-11-19 Ferx Incorporated Magnetically responsive composition
US6200547B1 (en) * 1994-01-26 2001-03-13 Ferx Incorporated Magnetically responsive compositions for carrying biologically active substances and methods of production and use
US5969111A (en) * 1994-04-14 1999-10-19 Board Of Regents, The University Of Texas System Texaphyrins substituted with imidazole are provided
RU2106146C1 (ru) 1995-07-17 1998-03-10 Институт элементоорганических соединений РАН Средство для подавления опухолевого роста
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
JPH10279502A (ja) * 1997-03-31 1998-10-20 Katsuro Tachibana 光感受性物質の励起方法
US6022526A (en) * 1997-07-30 2000-02-08 Pharmacyclics, Inc. Use of texaphyrins in detection of melanin and melanin metabolites diagnostic of melanotic melanoma
ATE376824T1 (de) 1999-01-13 2007-11-15 Alchemia Oncology Pty Ltd Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
HK1049787B (en) 1999-10-01 2014-07-25 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
WO2001032210A2 (en) * 1999-10-29 2001-05-10 Pharmacyclics, Inc. Compositions for treating atheroma and neoplastic tissue
US20030031676A1 (en) * 1999-10-29 2003-02-13 Pharmacyclics, Inc. Conjugate compounds for treating atheroma and other diseases
US7579338B2 (en) * 1999-10-29 2009-08-25 Pharmacyclics, Inc. Methods and compositions for treating atheroma, tumors and other neoplastic tissues
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US6638924B2 (en) 2000-08-30 2003-10-28 Pharmacyclics, Inc. Metallotexaphyrin derivatives
US7449454B2 (en) * 2000-08-30 2008-11-11 Pharmacyclics, Inc. Metallotexaphyrin derivatives
AU2001290580A1 (en) * 2000-08-30 2002-03-13 Pharmacyclics, Inc. Non-symmetric tripyrrannes in the synthesis of novel macrocycles
US20030188326A1 (en) 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
AU2002236458A1 (en) * 2000-11-17 2002-05-27 Pharmacyclics, Inc. Texaphyrin coordination compounds and uses thereof
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US6630454B2 (en) 2001-09-10 2003-10-07 Ramot At Tel-Aviv University Ltd. Method and pharmaceutical composition for the treatment of cancer
WO2003039327A2 (en) 2001-11-02 2003-05-15 Dana-Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective dna repair mechanisms and treatment thereof
EP1463511A4 (en) * 2001-12-13 2005-09-28 Pharmacyclics Inc COMBINATORY ANTICANCER THERAPY
CN1615129A (zh) * 2001-12-13 2005-05-11 环状药物公司 影响神经病学进展的方法
US6984734B2 (en) 2002-02-26 2006-01-10 Board Of Regents, The University Of Texas System Cyclo[n]pyrroles and methods thereto
US6723750B2 (en) 2002-03-15 2004-04-20 Allergan, Inc. Photodynamic therapy for pre-melanomas
US20030224422A1 (en) * 2002-04-08 2003-12-04 St. Jude Children's Research Hospital, Inc. Pre-and post therapy gene expression profiling to identify drug targets
US20040010218A1 (en) * 2002-07-11 2004-01-15 Henderson Barbara W. Photodynamic therapy for the enhancement of vascular permeability to aid in drug delivery to diseased tissues
JP2004077714A (ja) * 2002-08-15 2004-03-11 Fuji Xerox Co Ltd 光走査装置
US7981928B2 (en) * 2002-09-05 2011-07-19 Nanodynamics, Inc. Chemotherapy method using x-rays
US20080063605A1 (en) * 2004-05-20 2008-03-13 Wai-Fung Cheong Method of Enhancing Visualization of Atherosclerotic Plaque
JP2006224318A (ja) * 2005-02-15 2006-08-31 Brother Ind Ltd インクジェット記録装置
JP4972929B2 (ja) * 2005-03-25 2012-07-11 ニプロ株式会社 放射線増感剤
EP1704870A1 (en) 2005-03-25 2006-09-27 Nipro Corporation Use of iron compounds as radiosensitizers
WO2007012133A1 (en) * 2005-07-27 2007-02-01 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
US8319625B2 (en) * 2005-09-01 2012-11-27 Simplexgrinnell Lp Fire alarm textual notification related application
EA013877B1 (ru) * 2005-09-07 2010-08-30 Алкемиа Онколоджи Пти Лимитед Терапевтические композиции, содержащие гиалуроновую кислоту и терапевтические антитела, а также способы лечения
US20070072838A1 (en) 2005-09-26 2007-03-29 Pharmacyclics, Inc. High-purity texaphyrin metal complexes
US20070078119A1 (en) * 2005-09-30 2007-04-05 Pharmacyclics, Inc. Storage system for texaphyrin pharmaceutical formulations
JP5590882B2 (ja) * 2006-06-26 2014-09-17 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 化学療法増感剤としてのシステインに富む酸性分泌タンパク質(sparc)
US8287839B2 (en) * 2006-12-04 2012-10-16 Brookhaven Science Associates, Llc Carboranylporphyrins and uses thereof
US8444953B2 (en) * 2007-03-22 2013-05-21 Brookhaven Science Associates, Llc Symmetric and asymmetric halogen-containing metallocarboranylporphyrins and uses thereof
US20080279781A1 (en) * 2007-05-10 2008-11-13 Brookhaven Science Associates, Llc Glycosylated Carboranylporphyrins and Uses Thereof
RU2438718C1 (ru) * 2010-06-18 2012-01-10 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения сарком мягких тканей
US9662328B2 (en) 2010-11-29 2017-05-30 National Yang-Ming University Targeting human thymidylate kinase induces DNA repair toxicity in malignant tumor cells
TWI445696B (zh) 2010-11-29 2014-07-21 Univ Nat Yang Ming 標靶人類胸線核苷酸激酶誘導惡性腫瘤中的dna修復毒性
EP3154541A4 (en) 2014-06-11 2017-12-20 Board of Regents, The University of Texas System Texaphyrin-pt(iv) conjugates and compositions for use in overcoming platinum resistance
EP3554475A4 (en) * 2016-12-13 2020-08-19 Health Research, Inc. PHOTODYNAMIC THERAPY (PDT) IN THE NEAR INFRARED (NIR) IN COMBINATION WITH CHEMOTHERAPY
CN116264824A (zh) 2020-08-14 2023-06-16 德克萨斯大学系统董事会 用于锰化学疗法、光声成像和光热疗法的德克萨卟啉衍生物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5252720A (en) * 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
US4935498A (en) * 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5599923A (en) * 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5559207A (en) * 1989-03-06 1996-09-24 Board Of Regents, University Of Texas Texaphyrin metal complex mediated ester hydrolysis
US5607924A (en) * 1992-01-21 1997-03-04 Pharmacyclics, Inc. DNA photocleavage using texaphyrins
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
US5714328A (en) * 1995-06-07 1998-02-03 Board Of Regents, The University Of Texas System RNA photocleavage using texaphyrins

Also Published As

Publication number Publication date
CN1093766C (zh) 2002-11-06
EP0912196B1 (en) 2004-09-29
DE69730961T2 (de) 2005-11-24
EP0912196B9 (en) 2005-01-05
CN1213313A (zh) 1999-04-07
AU1833397A (en) 1997-08-20
EP0912196A1 (en) 1999-05-06
DE69730961D1 (de) 2004-11-04
KR19990082024A (ko) 1999-11-15
JP2000503989A (ja) 2000-04-04
IL125459A0 (en) 1999-03-12
US5776925A (en) 1998-07-07
ATE277637T1 (de) 2004-10-15
NZ331513A (en) 2001-10-26
AU715025B2 (en) 2000-01-13
NO983429L (no) 1998-09-24
WO1997026915A1 (en) 1997-07-31
NO983429D0 (no) 1998-07-24
HK1018588A1 (en) 1999-12-30

Similar Documents

Publication Publication Date Title
ES2227671T3 (es) Uso de una texafirina en la preparacion de un medicamento para usar con un agente quimioterapeutico en la quimiosensibilizacion del cancer.
Gill et al. Transition metal compounds as cancer radiosensitizers
KR102778887B1 (ko) 초음파역학 시술을 위한 미세거품-화학치료제 복합체
ES2321283T3 (es) Combinaciones de dmxaa y otros agentes anticancerigenos.
ES2307867T3 (es) Preparacion combinada que comprende un derivado de morfolinil antraciclina y un inhibidor de topoisomerasa ii.
ES2333400T3 (es) Composiciones y procedimientos para tratar linfonas.
ES2880291T3 (es) Nanopartículas conjugadas a un agente antinucleolina
ES2913119T3 (es) Cerdulatinib para tratar mieloma
JP7184775B2 (ja) 黄体化ホルモン放出ホルモン受容体(lhrh-r)コンジュゲートおよびその使用
Yao et al. Lectin-mediated pH-sensitive doxorubicin prodrug for pre-targeted chemotherapy of colorectal cancer with enhanced efficacy and reduced side effects
EA026168B1 (ru) Способы лечения рака
EP2993983B1 (en) Targeting corroles for tumor toxicity and mri
Liu et al. Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs
JP2010509241A (ja) 膜貫通ペプチドからなる自己凝集性ナノ粒子および抗癌剤の特異的腫瘍内送達のためのその利用
US6638924B2 (en) Metallotexaphyrin derivatives
US20170165382A1 (en) Nanocarriers for cancer treatment
CA2243392C (en) Use of a texaphyrin in the preparation of a medicament for use with a chemotherapeutic agent in cancer chemosensitization
KR20050026903A (ko) 암 치료에서 약물 감작제로서의 아릴옥시프로필아민
AU775680B2 (en) Liposome composition and method for administration of a radiosensitizer
HK1018588B (en) Use of a texaphyrin in the preparation of a medicament for use with a chemotherapeutic agent in cancer chemosensitization
Sarfaraz et al. Nanotechnology and it’s therapeutic application-a review
Huang et al. Advancing cancer therapy with a heptamethine carbocyanine dye-conjugated radionuclide drug
McGuire et al. Phase II study of esorubicin (4′-deozydoxorubicin) in advanced epithelial carcinoma of the ovary: A Gynecologic Oncology Group study
US20040171602A1 (en) Novel metallotexaphyrin derivatives
Liu et al. Cure of multidrug-resistant human B-cell lymphoma xenografts by